



May 1–3, 2010  
Vancouver Convention Centre  
Vancouver, BC, Canada

Saturday, May 1

Sunday, May 2

Monday, May 3

Tuesday, May 4

8:00am–10:00am  
**Topic Symposium**  
Critical Care Nephrology: New Concepts in Sepsis

10:15am–12:15pm  
**ASPEN Original Science**  
Issues in Dialytic Care

1:00pm–2:30pm  
**Poster Session I & Exhibits**  
Nephrology I

2:45pm–4:45pm  
**ASPEN Symposia**  
The Application of New Technologies to Understanding Renal Development, Disease, and Improved Diagnostics

**Topic Symposium**  
Neonatal and Infant Hypertension

5:00pm–6:30pm  
**PAS Opening General Session**  
President's Welcome  
Joseph St. Geme Leadership Award  
Keynote Lecture

8:00pm–9:30pm  
**ASPEN Member Reception**

7:00am–8:00am  
**Meet the Professor Breakfasts**  
William Schnaper: Negotiating a Faculty Position

8:00am–10:00am  
**ASPEN Original Science**  
**Abstract Program**  
Nephrology I

10:15am–12:15pm  
**ASPEN Symposia**  
Rocks in the Kidney – Mining New Data

10:15am–12:00pm  
**APS Presidential Plenary and Awards**

12:00pm–1:30pm  
**ASPEN CPC Fellow's Luncheon**  
Battle of the Brains

1:30pm–3:30pm  
**ASPEN Symposia**  
Glomerular Disease: New Perspectives on Pathogenesis and Treatment

3:30pm–5:30pm  
**ASPEN Presidential Address and Business Meeting**

5:30pm–7:30pm  
**Poster Session II & Exhibits**  
Nephrology II

8:00am–10:00am  
**Topic Symposia**  
Ethical and Social Implications of Providing Intensive Interventions to Infants for Whom the Clinical or Developmental Prognosis Is Uncertain

The Brain and Hypertension

10:15am–12:15pm  
**ASPEN Symposium**  
Role of Extracellular Matrix In Regulation of Kidney Development, Differentiation and Repair

**SPR Presidential Plenary and Awards**

12:30pm–1:45pm  
**ASPEN Awards Luncheon**  
Trainee Research Awards  
Henry L. Barnett Award  
Founders Award

1:00pm–3:00pm  
**March of Dimes Prize in Developmental Biology Lectures**

2:00pm–4:00pm  
**Original Science Abstract Program**  
Hypertension

3:15pm–5:15pm  
**State of the Art Plenary**  
An Update on Pediatric Drug Development Trials

4:15pm–6:15pm  
**ASPEN Original Science**  
**Abstract Program**  
Nephrology II

5:30pm–7:30pm  
**Poster Session III & Exhibits**

6:00pm–7:00pm  
**IPHA General Business Meeting**

**Continuing  
Education Credit**  
is through the PAS.  
See page 9 for  
complete information.



Join us in Vancouver where the American Society of Pediatric Nephrology (ASPEN) and the Pediatric Academic Societies (PAS) will, for the ninth year, host tightly aligned annual meetings. ASPEN symposia, joint symposia, original science, award and business activities will all be held at the Vancouver Convention Centre.

## Registration Information

There will be a single registration fee for the ASPEN/PAS meeting set at the PAS registration fee schedule. This registration fee allows participants to attend all ASPEN and PAS functions. Register by March 4th for substantial savings. Refer to page 111 of this guide for details. Please indicate that you are an ASPEN member when you register.

## Housing Information

Housing may be reserved online at [www.pas-meeting.org](http://www.pas-meeting.org) or refer to the housing form on page 109.

## Contact Information:

### For ASPEN information:

Lisa Thompson, ASPEN Executive Secretary  
ASPEN Central Office  
3400 Research Forest Dr., Ste. B-7  
The Woodlands, TX 77381  
Phone: 281-419-0052  
Email: [info@aspneph.com](mailto:info@aspneph.com)

### For housing, registration and general information:

PAS Program Office  
3400 Research Forest Drive, Suite B-7  
The Woodlands, TX 77381  
Phone: 281-419-0052  
Email: [info@pas-meeting.org](mailto:info@pas-meeting.org)  
URL: [www.pas-meeting.org](http://www.pas-meeting.org)

## Saturday, May 1

8:00am–10:00am

### 1110 Critical Care Nephrology: New Concepts in Sepsis Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians and researchers who wish to understand some updated concepts in the biology of sepsis and associated AKI, newer tools potentially available for use in determining outcomes, and treating patients in both the acute and chronic settings.

#### Objectives:

- Understand the current status of biological underpinnings of sepsis and how this may potentially guide future therapeutics
- Understand the future role of translational medicine and how it may affect decisions to treat and implications on outcomes
- Appreciate the central role that Sepsis associated Acute Kidney Injury plays in influencing morbidity and mortality in terms of cross-talk with other organ systems and what impact this has on care beyond the ICU environment

Chairs: Gail M. Annich, University of Michigan, Ann Arbor, MI and Annabelle Chua, Texas Children's Hospital- Baylor College of Medicine, Houston, TX

Sepsis and AKI related sepsis are responsible for a significant degree of morbidity and mortality in the pediatric population. Treatment protocols and

improved outcomes remain elusive. Currently these entities are becoming areas of in-depth investigation in terms of basic patho-physiology and clinical care pathways. The use of translational research methodologies to better define sepsis and its sequelae, predict outcomes and provide treatment options are also being intensively studied. The first speaker will present a state of the art in terms of our current understanding of the basic science of sepsis. The second speaker will present information on current biological profiling methods in terms of predicting patient outcomes. The third will provide an update on the specific entity of sepsis related AKI- clinical outcomes and approaches. The fourth will provide a unique look at the long-term outcomes of patients with sepsis related AKI after PICU care.

#### 8:00 AKI and Sepsis – From Bench to Bedside and Beyond

Annabelle Chua, Baylor College of Medicine, Texas Children's Hospital, Houston, TX  
Gail M. Annich, University of Michigan, Ann Arbor, MI

#### 8:05 The Biology of Sepsis

Thomas P. Shanley, University of Michigan Health System, Ann Arbor, MI

#### 8:30 Transcriptional Profiling in Sepsis

Hector R. Wong, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

#### 8:55 Sepsis-Associated AKI

Lakhmir Chawla, George Washington University, Washington, DC

#### 9:20 Renal Rehabilitation: After ICU Care for Sepsis-Associated AKI

Neesh Pannu, University of Alberta, Edmonton, AB, Canada

#### 9:45 Discussion

*Program developed by the American Society of Pediatric Nephrology, Pediatric Infectious Diseases Society and the Pediatric Academic Societies*

10:15am–12:15pm

### 1315A Issues in Dialytic Care

ASPEN Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians (physicians, nurses and allied health personnel) caring for children with end stage kidney disease requiring dialysis.

#### Objectives:

- Understand recent studies assessing outcomes of newer dialytic techniques
- Assess the evidence for incorporating new methods of blood pressure assessment in caring for dialysis patients
- Learn skills to deal with disruptive dialysis patients and options on how to incorporate physician extenders in dialysis programs to improve patient care

Chairs: Deepa Chand, Akron Children's Hospital, Akron, OH and Colin White, British Columbia Children's Hospital, Vancouver, BC, Canada

This session will highlight a number of important issues in dialytic care, including the emergence of new dialytic techniques including home, frequent and nighttime dialysis, as well as issues of BP control in dialysis. Practical issues such as management of the disruptive dialysis patient and the role of physician extenders in dialysis programs will also be addressed.

#### 10:15 Emerging Dialytic Techniques

David J. Askenazi, University of Alabama, Birmingham, AL

#### 10:45 Blood Pressure Control in Dialysis Patients

Janis Dionne, British Columbia Children's Hospital, Vancouver, BC, Canada

#### 11:15 The Disruptive Dialysis Patient

Lorraine Bell, McGill University Health Centre- Montreal Children's Hospital, Montreal, QC, Canada

#### 11:45 Physician Extenders: Role in Dialysis Programs

Michelle R. Mills, University of Michigan, C.S. Mott Children's Hospital, Ann Arbor, MI

1:00pm–2:30pm

**Nephrology Posters I and Opening Reception**

Vancouver Convention Centre

Details will be available in February

Posters Available for Viewing: 1:00pm–4:00pm

Author Attendance and Opening Reception: 1:00pm–2:30pm

1:00pm–4:00pm

**Commercial Exhibits Open and Posters Available for Viewing**

Vancouver Convention Centre

Posters Available for Viewing: 1:00pm–4:00pm

Author Attendance and Opening Reception: 1:00pm–2:30pm

2:45pm–4:45pm

**1620 Neonatal and Infant Hypertension**

Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians involved with the care of newborns and infants with hypertension

Objectives:

- Appreciate normative blood pressure data in newborns and infants and how to assess these data in the context of different measurement techniques
- Assess both the risks and benefits of antihypertensive medications (CCBs and ACE-inhibiting medications) in neonates and infants
- Evaluate the management of hypertension in NICU graduates and
- Understand the impact of the maternal treatment of hypertension as a risks to the developing fetus

Chairs: Julie R. Ingelfinger, Massachusetts General Hospital, Boston, MA and Tej K. Mattoo, Children's Hospital of Michigan, Detroit, MI

This symposium will focus on hypertension in the neonate and infant. Assessing blood pressure and normative data may be challenging in the neonate and infant, as there is a need to take into account gestational age as well as chronologic age for these patients. The risks and benefits of pharmacologic therapy will be discussed as well, given that the premature infant or young infant is still undergoing nephrogenesis and maturation of a number of systems including the renin-angiotensin system. There may also be factors impacting the fetus carried by a mother who has hypertension. Many of those infants diagnosed as neonates will eventually have resolution of their hypertension, but until they do, there is a need to optimize follow-up while minimizing risks.

**2:45 Normative Data and How To Assess Blood Pressure in the Neonate**

Janis Dionne, British Columbia Children's Hospital, Vancouver, BC, Canada

**3:10 Antihypertensives and Neonates: Risks and Benefits: ACEIs and CCBs**

Douglas L. Blowey, Children's Mercy Hospital, Kansas City, MO

**3:35 Management of Hypertension in NICU Graduates**

Joseph T. Flynn, Seattle Children's Hospital, Seattle, WA

**4:00 Maternal Treatment of Hypertension: Risks to Fetus**

Gideon Koren, The Hospital for Sick Children, Toronto, ON, Canada

**4:25 Discussion**

*Program developed by the American Society of Pediatric Nephrology, International Pediatric Hypertension Association and the Pediatric Academic Societies*

2:45pm–4:45pm

**1622A The Application of New Technologies to Understanding Renal Development, Disease, and Improved Diagnostics**

ASPEN Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians and scientists interested in the application of new methodologies to understanding disease pathogenesis and enhancing diagnostic precision.

Objectives:

- To become familiar with the concepts of epigenetic and microRNA mediated genomic regulation

- To incorporate this new understanding of epigenetics and microRNAs into the conceptual framework of renal development and disease pathogenesis
- To understand the how proteomics can be applied to biomarker discovery and tissue-based diagnosis

Chairs: Carlton Bates, Children's Hospital of Pittsburgh, Pittsburgh, PA and Rasheed Gbadegesin, Duke University Medical Center, Durham, NC

The completion of the Human Genome Project has set the stage for an explosion in research strategies that have defined new mechanisms of genomic regulation, such as epigenetics and microRNAs, and provided new tools for protein analysis and pathway characterization. These new mechanisms and methodologies will become increasingly important in our evolving understanding of normal development and disease pathogenesis, as well as in our diagnostic armamentarium. To provide a relevant framework for the practicing clinician to understand the impact of these new technologies, this symposium will highlight the role of epigenetic mechanisms and microRNAs in renal development and disease, and explore the application of proteomic methodologies for biomarker discovery and refined biopsy analysis.

**2:45 New Technologies Yield New Insights and New Tools for Nephrologists**

Lisa M. Guay-Woodford, University of Alabama at Birmingham, Birmingham, AL

**2:50 Epigenetic Control of Nephron Differentiation**

Samir S. El-Dahr, Tulane University School of Medicine, New Orleans, LA

**3:20 microRNAs in Kidney Development and Disease**

Jordan A. Kreidberg, Children's Hospital Boston, Boston, MA

**3:50 Genome Search for Mechanistic Biomarkers: The Potential for Personalized Medicine**

Sudhir Srivastava, National Cancer Institute, Bethesda, MD

**4:20 Tissue Proteomics: A New Investigative Tool for Renal Biopsy Analysis**

John Sedor, Case Western Reserve University, Cleveland, OH

*Program developed by the American Society of Pediatric Nephrology*

5:00pm–6:30pm

**1800 PAS Opening General Session**

Vancouver Convention Centre

Presidents Welcome, Joseph St. Geme Leadership Award, Kenote Lecture

8:00pm–9:30pm

**1970A ASPN Member Reception**

**Sunday, May 2**

7:00am–8:00am

**2046 Nephrology: Negotiating a Faculty Position**

PAS Meet the Professor Breakfast

In this interactive session, prospective academic pediatric nephrologists will explore how to define their career goals and learn the parameters involved in a Department's recruiting a faculty member.

**H. William Schnaper**

Professor and Vice Chair of Pediatrics  
Northwestern University's Feinberg School of Medicine, Chicago, IL



8:00am–10:00am

**2130 Nephrology Platform I**

Vancouver Convention Centre

Details will be available in February

10:15am–11:45am

**2305 APS Presidential Plenary and Awards**

Vancouver Convention Centre

10:15am–12:15pm

**2310A Rocks in the Kidney – Mining New Data**  
ASPNTopic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians and researchers who wish to learn more about the pathophysiology and management of stone disease in children.

Objective:

- Understand the genetics and clinical approaches to managing pediatric patients with nephrolithiasis

Chairs: Craig B. Langman, Children's Memorial Hospital, Chicago, IL

Kidney stones continue to be a clinical challenge for pediatricians and subspecialists with increasing rates of stone formation and stone-related complications in children. This session will focus on the evaluation and management of the child with nephrolithiasis. A review of the common causes of stone disease such as hypercalciuria will be presented but also the newer etiologies including environmental exposures such as melamine will be discussed. Participants will learn insights into genetic factors associated with stone formation as well as novel risk factors like renal phosphate wasting. A review of the indications for interventional management of pediatric kidney stones will also be discussed.

**10:15 Melamine-Induced Stones: What Do We Know So Far?**

Craig B. Langman, Children's Memorial Hospital, Chicago, IL

**10:45 Calcium and Phosphate Homeostasis: Concerted Interplay of New Regulators**

David Bushinsky, University of Rochester School of Medicine and Dentistry, Rochester, NY

**11:15 Phosphate Wasting and Nephrolithiasis: Is There a Link?****11:45 Interventional Management of Stones**

Yegappan Lakshmanan, Children's Hospital of Michigan, Detroit, MI

Program developed by the American Society of Pediatric Nephrology

12:00pm–1:30pm

**2422A ASPN CPC Fellow's Luncheon**  
**Battle of the Brains**

Objectives:

- Evaluate pediatric renal pathology specimens
- Understand treatment controversies and research opportunities in a variety of renal diseases
- Participate in networking amongst pediatric nephrologists

Chairs: Victoria Norwood, University of Virginia Children's Hospital, Charlottesville, VA and Patrick Walker, Nephropathology Associates, Little Rock, AR

Interactive clinical renal pathology conference for fellows and selected pediatric nephrology and pathology faculty in which cases will be presented for evaluation and spirited discussion. The objectives are to stimulate interactions between fellow and members of the society, encourage broad discussions of renal pathology, pathophysiology, and treatment conundrums and stimulate the development of potential research questions. Space is limited.

Program developed by the American Society of Pediatric Nephrology

1:30pm–3:30pm

**2695A Glomerular Disease: New Perspectives on Pathogenesis and Treatment**  
ASPN Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians and researchers who wish to learn more about the new advances in pathogenesis, diagnosis, and management of common glomerulonephritides.

Objectives:

- At the conclusion of this session, participants should be better able to understand the new advances in pathogenesis, diagnosis, and management of common glomerulonephritides

Chairs: Debbie Gipson, University of North Carolina, Chapel Hill, NC and Patrick Walker, Nephropathology Associates, Little Rock, AR

Glomerulonephritides remain a common cause of kidney disease in children and adolescents. Recent studies have significantly advanced our understanding of the underlying pathophysiology, and have led to the elucidation of

improved treatment options. The first speaker will discuss recent advances in the pathogenesis of IgA Nephropathy, the most common form of glomerulonephritis globally. The second speaker will update the audience on new therapeutic trials for Membranoproliferative Glomerulonephritis, a disease with very limited treatment options thus far. The third speaker will discuss recent advances in the pathogenesis and treatment of Focal Segmental Glomerulosclerosis, a common cause of end-stage renal disease in the pediatric population. The fourth speaker will provide an update on the pathogenesis and treatment of Lupus Nephritis, an important cause of renal failure in adolescents.

**1:30 Pathogenesis of IgA Nephropathy**

Jan Novak, University of Alabama at Birmingham, Birmingham, AL

**2:00 New Therapies for Membranoproliferative Glomerulonephritis**

Christoph Licht, Hospital for Sick Children, Toronto, ON, Canada

**2:30 Update on Pathogenesis and Treatment of Focal Segmental Glomerulosclerosis**

Rasheed Gbadegesin, Duke University Medical Center, Durham, NC

**3:00 Therapeutic Approaches to Lupus Nephritis**

Keisha Gibson, University of North Carolina, Chapel Hill, NC

Program developed by the American Society of Pediatric Nephrology

**2815A ASPN Presidential Address and Business Meeting**

Vancouver Convention Centre

**ASPN Presidential Address**

Lisa M. Satlin, Mount Sinai School of Medicine, New York, NY

4:00pm–7:30pm

**Commercial Exhibits Open and Posters Available for Viewing**

Vancouver Convention Centre

Posters Available for Viewing: 4:00pm–7:30pm

Author Attendance: 5:30pm–7:30pm

5:30pm–7:30pm

**Nephrology Poster Session II**

Vancouver Convention Centre

Details will be posted in February

**Monday, May 3**

8:00am–10:00am

**3060 Ethical and Social Implications of Providing Intensive Interventions to Infants for Whom the Clinical or Developmental Prognosis Is Uncertain**

Topic Symposium ~ Vancouver Convention Centre

Target Audience: Neonatologists, pediatric nephrologists, ethicists, transplant specialists, intensivists, nurses, social workers.

Objectives:

- Understand the ethical and social implications of decisions to offer or withhold intensive interventions (tracheostomy, mechanical ventilation, dialysis, and transplantation) to a child with uncertain clinical or developmental prognosis
- Consider whether ethical concerns about limited resources, quality of life, and parental preferences, should be taken into account when considering intensive interventions in these children with profound disabilities
- Reflect on how to respond to families who make requests that the clinical team does not support

Chairs: Lorraine Bell, McGill University Health Centre- Montreal Children's Hospital, Montreal, QC, Canada and Benjamin S. Wilfond, National Human Genome Research Institute, Seattle, WA

Profound moral decisions sometimes arise regarding intensive and potentially burdensome interventions for infants with uncertain developmental or clinical prognoses. This includes infants with complex medical conditions and those who are likely to have profound developmental disabilities because of congenital syndromes or perinatal complications. These decisions can evoke strong emotions. Some may feel the interventions are inappropriate; others may believe that parents requesting such therapies must be supported. These issues often arise in the newborn critical care setting, in the context of decisions about mechanical ventilation and tracheostomy, complex high risk surgery, and initiation of acute or chronic renal replacement therapy. Are there ethical justifications for limiting parental requests? We will explore how the definitions and value of profound disability can impact the opinions of health care professionals and influence disagreement among providers and parents. We will examine the ethical justifications for limiting parental requests in some circumstances, and how we should approach parents who make them.

- 8:00 Ethical Issues in Care of the Medically Complex Patient**  
Lorraine Bell, McGill University Health Centre- Montreal Children's Hospital, Montreal, QC, Canada
- 8:05 Approaching Interventions in Children in the NICU Who Are Likely To Have Profound Disabilities (Trisomy Syndromes)**  
Mark R. Mercurio, Yale University School of Medicine, New Haven, CT
- 8:30 Renal Replacement Therapy in the Neonatal Intensive Care: Pushing the Boundaries of Care – What Are the Limits?**  
Gina-Marie Barletta, Helen DeVos Children's Hospital, Grand Rapids, MI
- 8:55 Ethical Considerations in Transplantation in Infants with Syndromes and Chronic Disabilities**  
Aviva Goldberg, University of Manitoba, Winnipeg, MB, Canada
- 9:20 Ethical Justifications for Limiting Parental Requests and How To Approach Parents Who Make Requests**  
Norman Fost, University of Wisconsin, Madison, WI
- 9:45 Discussion**

*Program developed by the American Society of Pediatric Nephrology and the Pediatric Academic Societies*

8:00am–10:00am

**3080 The Brain and Hypertension**  
Topic Symposium ~ Vancouver Convention Centre

Target Audience: Clinicians caring for children with hypertension and those at risk for development of hypertension due to medications that affect the central nervous system.

- Objectives:
- Recognize the impact of hypertension on neurocognition and the brain
  - Understand the effects that ADHD medications have on blood pressure and the risk for hypertension
  - Appreciate the central nervous system effects of antihypertensive medications
  - Recognize the short and long term outcomes of hypertensive encephalopathy

Chairs: Kevin Meyers, Children's Hospital of Philadelphia, Philadelphia, PA and Donald L. Batsky, Emory Children's Center, Atlanta, GA

The primary focus of this symposium will be on effects of hypertension on the brain and central nervous system as a target organ. Various aspects of the effects of hypertension on the brain in the pediatric population will be explored, such as neurocognition in the patient with hypertension. Some therapies for conditions affecting the central nervous system such as stimulant therapy in attention deficit disorders may result in elevated blood pressure, so it is important to recognize these factors. There are a number of centrally active antihypertensives that will be reviewed, and one of the more dramatic results of hypertension, PRES (posterior reversible encephalopathy syndrome) as a manifestation of hypertensive encephalopathy, will be discussed as well.

- 8:00 Neurocognition and the Brain in Hypertension**  
Marc Lande, Golisano Children's Hospital at Strong Pediatrics, Rochester, NY
- 8:25 ADHD Medications and Hypertension**  
Paul Hammerness, Massachusetts General Hospital, Cambridge, MA
- 8:50 Central Effects of Antihypertensives**  
Debra Diz, Hypertension and Vascular Research Center, Wake Forest University, Winston-Salem, NC
- 9:15 A PRESing Matter: Posterior Reversible Encephalopathy Syndrome And Hypertension: Resolved and Unresolved Issues**  
Kenji Ishikura, Tokyo Metropolitan Kiyose Children's Hospital, Tokyo, Japan
- 9:40 Discussion**

*Program developed by the American Society of Pediatric Nephrology, International Pediatric Hypertension Association, Japan Pediatric Society and the Pediatric Academic Societies*

10:15am–12:15pm

**3250 SPR Presidential Plenary and Awards**  
Vancouver Convention Centre

10:15am–12:15pm

**3275A Role of Extracellular Matrix in Regulation of Kidney Development, Differentiation and Repair**  
ASP Topic Symposium ~ Vancouver Convention Centre

Target Audience: Basic science, renal physiology.

Objectives:

- Define the diverse roles of the extracellular matrix in kidney development and differentiation
- Understand how the extracellular matrix helps regulate acid-base balance and repair from acute kidney injury

Chairs: George J. Schwartz, University of Rochester Medical Center, Rochester, NY and Norman D. Rosenblum, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada

The extracellular matrix performs key yet under-recognized roles in the development, differentiation and repair of kidney tissue components. In this symposium, speakers will discuss the role of the extracellular matrix in a) renal development; b) pathophysiology of chronic glomerulonephritis; c) recovery from acute kidney injury; and d) response to acidosis.

- 10:15 The Extracellular Matrix in the Kidney**  
George J. Schwartz, University of Rochester Medical Center, Rochester, NY
- 10:20 ECM Regulates Development and Function of the Glomerular Filtration Barrier**  
Jeff Miner, Washington University School of Medicine, St. Louis, MO
- 10:45 Extracellular Matrix in Chronic Kidney Disease**  
Allison A. Eddy, University of Washington, Seattle, WA
- 11:10 Integrins in Renal Development**  
Roy Zent, Vanderbilt University School of Medicine, Nashville, TN
- 11:35 Hensin in the ECM Regulates Response to Acidosis and Stimulates Differentiation**  
George J. Schwartz, University of Rochester Medical Center, Rochester, NY
- 12:00 Discussion**

*Program developed by the American Society of Pediatric Nephrology*



12:30pm–1:45pm

**3340A ASPN Awards Luncheon**

Vancouver Convention Centre

**Trainee Research Awards**

Introduction and Presenter: Susan L. Furth, Chief, Division of Pediatric Nephrology, Children's Hospital of Philadelphia, Philadelphia, PA

**Henry L. Barnett Award - American Academy of Pediatrics Section on Nephrology**

Presenter and Recipient to be determined

**Founder's Award**

Introduction: Lisa M. Satlin, Chief, Division of Nephrology, Mount Sinai School of Medicine, New York, NY

*Recipients to be determined*

1:00pm–3:00pm

**3350 March of Dimes Prize in Developmental Biology Lectures**

Vancouver Convention Centre

2:00pm–4:00pm

**3457 PAS Original Science Abstract Program: Hypertension**

Vancouver Convention Centre

Details will be available in February

3:15pm–5:15pm

**3465 An Update on Pediatric Drug Development Trials**

State of the Art Plenary ~ Vancouver Convention Centre

Target Audience: Healthcare professionals who prescribe medications to children, pediatric policy makers and healthcare professionals interested in affecting change to the policies pertaining to pediatric drug development.

**Objectives:**

- At the conclusion of this session, the participant should be better able to:
- Understand the impact of the current pediatric regulations enacted in the US and Europe on pediatric drug development
- Understand the necessary steps in characterizing the drug before the onset of pediatric clinical trials
- Understand the steps to be taken to develop pediatric clinical trials units
- Understand the process taken by industry to successfully complete pediatric clinical trials and achieve regulatory compliance

Chairs: H. William Schnaper, Feinberg School of Medicine and Children's Memorial Hospital, Chicago, IL and Wayne R. Snodgrass, University of Texas, Medical Branch, Galveston, TX

Legislative initiatives have placed pediatric considerations at the forefront of drug development. Unlike products developed for adults, regulatory agencies play a major role in driving pediatric clinical trial development. A PAS symposium in 2009 presented the necessary partnerships to ensure that pediatric research yields information valuable to all parties involved - especially children. This year, the leadership of the FDA Office of Pediatric Therapeutics will update attendees on current and future plans for pediatric drug development including ethical considerations. Substantial work necessary before a drug is ready for formal trials in children will be discussed including formulation development, safety assessment in juvenile animal models and assessments of pharmacokinetics, pharmacodynamics and dosing. A limiting factor for trial success is adequate recruitment in sites with clinical trials expertise thus an approach to developing a clinical trials center will be discussed. Finally, industry's approach to performing these critical trials will be presented including country, site, and investigator selection.

**3:15 Introduction**

Wayne R. Snodgrass, University of Texas, Medical Branch, Galveston, TX

**3:20 Pediatric Clinical Trials: FDA as Your "Federal" Partner: 10 Years/300 Products/600 Studies Later**

Dianne Murphy, Food and Drug Administration, Rockville, MD

**3:40 An Overview of Pediatric Drug Development from an FDA Perspective**

Robert "Skip" Nelson, Food and Drug Administration, Silver Spring, MD

**4:00 What Does One Need To Know about a Drug before the Trial Begins?**

John S. Bradley, Rady Children's Hospital, San Diego, CA

**4:20 Building a Pediatric Clinical Trials Unit**

Jeffrey L. Blumer, Rainbow Babies' Hospital, Cleveland, OH

**4:40 Operational Challenges for Pediatric Drug Development Trials**

Ronald J. Portman, Bristol Myers Squibb, Princeton, NJ

**5:00 Conclusions and Discussions**

H. William Schnaper, Feinberg School of Medicine and Children's Memorial Hospital, Chicago, IL

*Program developed by the American Society of Pediatric Nephrology and the Pediatric Academic Societies*

4:15pm–6:15pm

**3645 Nephrology Platform II**

Vancouver Convention Centre

Details will be available in February

5:30pm–7:30pm

**3700 Poster Session III**

Vancouver Convention Centre

Details will be available in February

Posters Available for Viewing: 4:00pm–7:30pm

Author Attendance: 5:30pm–7:30pm

6:00pm–7:00pm

**3860 IPHA General Business Meeting**

All current IPHA members as well as other interested individuals are invited to join us for discussion of current and upcoming IPHA activities

Visit the  
American Society of  
Pediatric Nephrology  
at  
[www.aspneph.com](http://www.aspneph.com)